Polypharmacology report
- Pubchem Assay ID: 686971
- Title: qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-IDH1KD cell line
- Target: L3MBTL1
Abreviations used here:
- kA:The number of active compounds known to target the pattern
- KA:The total number of active compounds(IC50 < 10-6)
- kB:The number of inactive compounds known to target the pattern
- KB:The total number of inactive compounds(IC50 >10-6)
- Odds Ratio: (kA/kB) / ( (KA-kA) / (KB - kB) )
Individual statistics for L3MBTL1 in the assay 686971:
- kA: 115
- KA: 7342
- kB: 1271
- KB: 227332
- Odds Ratio: 2.8
Table 1. Poly-pharmacological protein patterns (with L3MBTL1) enriched among Active molecules
# | Target Duplet | P-value FDR adjusted |
Odds Ratio | kA | KA | kB | KB | Polypharmacology triplets | View Compounds details |
View Pattern Profile |
1 | L3MBTL1 and IDH1 | 1.22e-66 | 73.7 | 59 | 7342 | 25 | 227332 | Polypharmacology | Molecules | Target Profile |
2 | L3MBTL1 and TNFRSF10B | 5.55e-29 | 33.2 | 31 | 7342 | 29 | 227332 | Polypharmacology | Molecules | Target Profile |
3 | L3MBTL1 and ATXN2 | 8.85e-28 | 32.2 | 30 | 7342 | 29 | 227332 | Polypharmacology | Molecules | Target Profile |
4 | L3MBTL1 and SMAD3 | 1.63e-31 | 29.4 | 35 | 7342 | 37 | 227332 | Polypharmacology | Molecules | Target Profile |
5 | L3MBTL1 and GMNN | 3.66e-33 | 15.6 | 47 | 7342 | 94 | 227332 | Polypharmacology | Molecules | Target Profile |
6 | L3MBTL1 and IL1B | 3.55e-24 | 11.9 | 39 | 7342 | 102 | 227332 | Polypharmacology | Molecules | Target Profile |
7 | L3MBTL1 and TDP1 | 8.52e-55 | 9.6 | 101 | 7342 | 331 | 227332 | Polypharmacology | Molecules | Target Profile |
8 | L3MBTL1 and RBBP8 | 1.76e-24 | 9.5 | 45 | 7342 | 148 | 227332 | Polypharmacology | Molecules | Target Profile |
9 | L3MBTL1 and SENP8 | 8.22e-16 | 8.5 | 31 | 7342 | 114 | 227332 | Polypharmacology | Molecules | Target Profile |
10 | L3MBTL1 and SIX1 | 1.22e-21 | 6.9 | 49 | 7342 | 220 | 227332 | Polypharmacology | Molecules | Target Profile |
11 | L3MBTL1 and PPP1CA | 1.15e-10 | 6.9 | 24 | 7342 | 108 | 227332 | Polypharmacology | Molecules | Target Profile |
12 | L3MBTL1 and XBP1 | 0.000101 | 123.9 | 4 | 7342 | 1 | 227332 | Polypharmacology | Molecules | Target Profile |
13 | L3MBTL1 and CTNNB1 | 3.84e-09 | 82.7 | 8 | 7342 | 3 | 227332 | Polypharmacology | Molecules | Target Profile |
14 | L3MBTL1 and S1PR3 | 1.37e-05 | 77.5 | 5 | 7342 | 2 | 227332 | Polypharmacology | Molecules | Target Profile |
15 | L3MBTL1 and TNFSF10 | 6.99e-11 | 62.0 | 10 | 7342 | 5 | 227332 | Polypharmacology | Molecules | Target Profile |
16 | L3MBTL1 and HTR1A | 3.36e-09 | 46.5 | 9 | 7342 | 6 | 227332 | Polypharmacology | Molecules | Target Profile |
17 | L3MBTL1 and NLRP3 | 7.51e-05 | 38.7 | 5 | 7342 | 4 | 227332 | Polypharmacology | Molecules | Target Profile |
18 | L3MBTL1 and NCOA3 | 1.66e-16 | 37.7 | 17 | 7342 | 14 | 227332 | Polypharmacology | Molecules | Target Profile |
19 | L3MBTL1 and RORA | 8.81e-06 | 37.2 | 6 | 7342 | 5 | 227332 | Polypharmacology | Molecules | Target Profile |
20 | L3MBTL1 and S1PR4 | 8.81e-06 | 37.2 | 6 | 7342 | 5 | 227332 | Polypharmacology | Molecules | Target Profile |
21 | L3MBTL1 and GALR2 | 1.80e-09 | 34.4 | 10 | 7342 | 9 | 227332 | Polypharmacology | Molecules | Target Profile |
22 | L3MBTL1 and HTR1E | 2.62e-11 | 33.8 | 12 | 7342 | 11 | 227332 | Polypharmacology | Molecules | Target Profile |
23 | L3MBTL1 and MMP14 | 3.85e-13 | 33.4 | 14 | 7342 | 13 | 227332 | Polypharmacology | Molecules | Target Profile |
24 | L3MBTL1 and NOD2 | 6.70e-16 | 33.0 | 17 | 7342 | 16 | 227332 | Polypharmacology | Molecules | Target Profile |
25 | L3MBTL1 and TSHR | 3.44e-09 | 31.0 | 10 | 7342 | 10 | 227332 | Polypharmacology | Molecules | Target Profile |
26 | L3MBTL1 and TNF | 4.34e-12 | 25.5 | 14 | 7342 | 17 | 227332 | Polypharmacology | Molecules | Target Profile |
27 | L3MBTL1 and GSK3A | 1.57e-05 | 19.7 | 7 | 7342 | 11 | 227332 | Polypharmacology | Molecules | Target Profile |
28 | L3MBTL1 and NLRP1 | 1.57e-05 | 19.7 | 7 | 7342 | 11 | 227332 | Polypharmacology | Molecules | Target Profile |
29 | L3MBTL1 and NPY2R | 9.20e-10 | 17.5 | 13 | 7342 | 23 | 227332 | Polypharmacology | Molecules | Target Profile |
30 | L3MBTL1 and FASN | 0.00018 | 16.9 | 6 | 7342 | 11 | 227332 | Polypharmacology | Molecules | Target Profile |
31 | L3MBTL1 and PPP5C | 0.0014 | 15.5 | 5 | 7342 | 10 | 227332 | Polypharmacology | Molecules | Target Profile |
32 | L3MBTL1 and KCNQ1 | 6.90e-14 | 14.8 | 20 | 7342 | 42 | 227332 | Polypharmacology | Molecules | Target Profile |
33 | L3MBTL1 and STAT3 | 2.73e-06 | 14.7 | 9 | 7342 | 19 | 227332 | Polypharmacology | Molecules | Target Profile |
34 | L3MBTL1 and STAT1 | 2.07e-07 | 13.6 | 11 | 7342 | 25 | 227332 | Polypharmacology | Molecules | Target Profile |
35 | L3MBTL1 and UCHL5 | 2.23e-09 | 13.6 | 14 | 7342 | 32 | 227332 | Polypharmacology | Molecules | Target Profile |
36 | L3MBTL1 and HSP90AA1 | 2.50e-12 | 12.8 | 19 | 7342 | 46 | 227332 | Polypharmacology | Molecules | Target Profile |
37 | L3MBTL1 and SLC5A7 | 9.72e-06 | 12.1 | 9 | 7342 | 23 | 227332 | Polypharmacology | Molecules | Target Profile |
38 | L3MBTL1 and PTBP1 | 6.92e-07 | 11.8 | 11 | 7342 | 29 | 227332 | Polypharmacology | Molecules | Target Profile |
39 | L3MBTL1 and SLC12A5 | 8.47e-08 | 10.9 | 13 | 7342 | 37 | 227332 | Polypharmacology | Molecules | Target Profile |
40 | L3MBTL1 and HCRTR1 | 1.19e-09 | 10.0 | 17 | 7342 | 53 | 227332 | Polypharmacology | Molecules | Target Profile |
41 | L3MBTL1 and ATAD5 | 7.39e-13 | 9.8 | 23 | 7342 | 73 | 227332 | Polypharmacology | Molecules | Target Profile |
42 | L3MBTL1 and GNAO1 | 0.0024 | 9.3 | 6 | 7342 | 20 | 227332 | Polypharmacology | Molecules | Target Profile |
43 | L3MBTL1 and MPI | 1.22e-09 | 8.3 | 19 | 7342 | 71 | 227332 | Polypharmacology | Molecules | Target Profile |
44 | L3MBTL1 and PTK2 | 0.00065 | 6.5 | 9 | 7342 | 43 | 227332 | Polypharmacology | Molecules | Target Profile |